On the Record · Seagen
Seagen competitors, on the record
The companies Seagen itself names as competitors in its annual reports, 2020 to 2022, each with the sentence it appears in and the filing it came from.
Who Seagen names
| Company | Named in |
|---|---|
| Acrotech Biopharma | 2022 |
| Bristol-Myers Squibb | 2022 |
| Janssen | 2022 |
| Merck | 2022 |
In its own words
Acrotech Biopharma, Bristol-Myers Squibb, Merck
Word for word“Bristol-Myers Squibb's, or BMS's nivolumab and Merck's pembrolizumab are approved for the treatment of certain patients with relapsed or refractory classical Hodgkin lymphoma, and Acrotech Biopharma's pralatrexate and belinostat are approved for relapsed or refractory systemic anaplastic large cell lymphoma, or sALCL, among other T-cell lymphomas.” 10-K for 2022
Janssen
Word for word“With respect to PADCEV, other treatments in pretreated metastatic urothelial cancer include sacituzumab govitecan (a Trop-2-directed antibody and topoisomerase inhibitor conjugate), checkpoint inhibitor monotherapy, generic chemotherapy and, for patients with select FGFR genetic alterations, Janssen's erdafitinib.” 10-K for 2022
Read from Seagen’s annual reports (10-K for 2022, 10-K for 2021, 10-K for 2020) and the financial data it files with the SEC, as of 2023-02-15. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.